- Home
- NBH vs PROF Comparison
NBH vs PROF Comparison
Compare NBH & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBH | PROF |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 301.2M | 248.8M |
| IPO Year | 2002 | 2017 |
Fundamental Metrics
Financial Performance| Metric | NBH | PROF |
|---|---|---|
| Price | $9.91 | $6.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 71.7K | ★ 102.1K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,098,000.00 |
| Revenue This Year | N/A | $92.40 |
| Revenue Next Year | N/A | $64.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 50.73 |
| 52 Week Low | $9.78 | $3.92 |
| 52 Week High | $10.72 | $8.95 |
Technical Indicators
Market Signals| Indicator | NBH | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 28.62 | 45.04 |
| Support Level | $9.78 | $6.51 |
| Resistance Level | $10.46 | $6.94 |
| Average True Range (ATR) | 0.09 | 0.27 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 4.35 | 29.95 |
Price Performance
Historical ComparisonAbout NBH Neuberger Berman Municipal Fund Inc.
Neuberger Berman Municipal Fund Inc is a closed-end management investment company that invests mainly in municipal securities. The company aims to provide common stockholders a high level of current income exempt from Federal income tax.
About PROF Profound Medical Corp.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.